Geode Capital Management
FBRX icon

Geode Capital Management’s Forte Biosciences FBRX Stock Holding History

Geode Capital Management’s Portfolio FBRX Stock Details FBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.25M Buy
125,442
+833
+0.7% +$24K ﹤0.01% 2934
2025
Q4 		$3.4M Buy
124,609
+16,291
+15% +$286K ﹤0.01% 2953
2025
Q3 		$1.63M Buy
108,318
+44,208
+69% +$509K ﹤0.01% 3252
2025
Q2 		$829K Buy
64,110
+4,028
+7% +$34.7K ﹤0.01% 3388
2025
Q1 		$466K Buy
60,082
+43,205
+256% +$510K ﹤0.01% 3568
2024
Q4 		$383K Buy
16,877
+2,607
+18% +$31K ﹤0.01% 3691
2024
Q3 		$79.9K Buy
14,270
+418
+3% +$4.3K ﹤0.01% 4162
2024
Q2 		$186K Buy
13,852
+115
+0.8% +$1.86K ﹤0.01% 3938
2024
Q1 		$241K Buy
13,737
+273
+2% +$4.76K ﹤0.01% 3876
2023
Q4 		$277K Buy
13,464
+5,129
+62% +$71.7K ﹤0.01% 3832
2023
Q3 		$138K Buy
8,335
+602
+8% +$13.3K ﹤0.01% 4135
2023
Q2 		$201K Buy
7,733
+5
+0.1% +$130 ﹤0.01% 4038
2023
Q1 		$195K Buy
7,728
+30
+0.4% +$755 ﹤0.01% 4066
2022
Q4 		$192K Buy
7,698
+56
+0.7% +$1.44K ﹤0.01% 4127
2022
Q3 		$204K Buy
7,642
+178
+2% +$5.66K ﹤0.01% 4202
2022
Q2 		$242K Sell
7,464
-2,811
-27% -$89.3K ﹤0.01% 4147
2022
Q1 		$375K Buy
10,275
+56
+0.5% +$2.12K ﹤0.01% 4084
2021
Q4 		$546K Buy
10,219
+6,164
+152% +$415K ﹤0.01% 4000
2021
Q3 		$300K Sell
4,055
-3,083
-43% -$1.71M ﹤0.01% 4268
2021
Q2 		$6M Buy
7,138
+3,636
+104% +$3.28M ﹤0.01% 2793
2021
Q1 		$3M Buy
3,502
+382
+12% +$313K ﹤0.01% 3052
2020
Q4 		$2.84M Buy
3,120
+61
+2% +$57.3K ﹤0.01% 2892
2020
Q3 		$3.71M Buy
3,059
+2,281
+293% +$1.51M ﹤0.01% 2563
2020
Q2 		$283K Sell
778
-261
-25% -$117K ﹤0.01% 3561
2020
Q1 		$475K Buy
1,039
+161
+18% +$62.9K ﹤0.01% 3290
2019
Q4 		$175K Buy
878
+103
+13% +$23.3K ﹤0.01% 3841
2019
Q3 		$192K Sell
775
-1
-0.1% -$1.52K ﹤0.01% 3782
2019
Q2 		$1.94M Buy
776
+57
+8% +$169K ﹤0.01% 2974
2019
Q1 		$2.93M Buy
719
+154
+27% +$595K ﹤0.01% 2620
2018
Q4 		$1.74M Buy
565
+110
+24% +$474K ﹤0.01% 2840
2018
Q3 		$2.66M Buy
455
+183
+67% +$697K ﹤0.01% 2728
2018
Q2 		$950K Buy
272
+27
+11% +$98.9K ﹤0.01% 3205
2018
Q1 		$1.09M Buy
245
+4
+2% +$18.5K ﹤0.01% 3085
2017
Q4 		$927K Buy
241
+33
+16% +$132K ﹤0.01% 3134
2017
Q3 		$971K Buy
208
+25
+14% +$111K ﹤0.01% 3130
2017
Q2 		$825K Buy
+183
New +$1.03M ﹤0.01% 3178

Other funds holding FBRX

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

Geode Capital Management's FBRX Position: Q1 2026 in Review

Geode Capital Management increased its Forte Biosciences (FBRX) stake by 0.67% in Q1 2026, buying an estimated $24K and bringing the position to 125,442 shares worth $3.25M. The position accounts for ﹤0.01% of the portfolio, ranked #2934.

Geode Capital Management first reported a position in FBRX in Q2 2017 and has held it in 36 quarters since. The position peaked at $6M in Q2 2021. 68 funds tracked by Wall St. Rank hold FBRX as of Q1 2026.

  • Geode Capital Management held 125,442 shares of Forte Biosciences worth $3.25M as of Q1 2026.
  • Geode Capital Management bought 833 Forte Biosciences shares in Q1 2026, an estimated $24K.
  • Forte Biosciences made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #2934 holding.
  • Geode Capital Management first reported a position in Forte Biosciences in Q2 2017 and has held it in 36 quarters since.
  • Geode Capital Management's Forte Biosciences position peaked at $6M in Q2 2021.
  • 68 funds tracked by Wall St. Rank held Forte Biosciences as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.